HQL offers a 14.2% dividend yield and diverse exposure to healthcare and life science companies. Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price ...
abrdn Life Sciences Investors remains a buy for high-yield seekers, offering a 10.1% dividend yield and diversified healthcare exposure. HQL trades at a 7.92% discount to NAV, with its share price ...
$HQL insiders have traded $HQL stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales. Here’s a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results